Skip to main
DCTH
DCTH logo

Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems (DCTH) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 13%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Delcath Systems Inc is projected to experience significant revenue growth, with total revenues anticipated to reach $338.7 million by 2032, up from $82.3 million in 2025. The company has demonstrated consistent quarter-over-quarter growth in HEPZATO-related revenues, indicating strong market adoption since the product's launch, with a notable 37% increase from $10.0 million in 3Q24 to $13.7 million in 4Q24. Additionally, Delcath's strategic focus on expanding its business in European markets, alongside successful new site activations, is expected to support ongoing financial performance and enhance its growth potential in 2025.

Bears say

Delcath Systems Inc has been facing significant operational challenges, evidenced by increasing costs associated with the research and development of its Melphalan Hydrochloride product and Hepatic Delivery System, which may adversely impact its profitability margins. Furthermore, the company has not demonstrated a considerable revenue growth trajectory, raising concerns about its market position and sustainability in the competitive oncology sector. Finally, the financial reports indicate a reliance on substantial external funding, which could be a risk factor given the volatility in investor sentiment and market conditions.

Delcath Systems (DCTH) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Delcath Systems (DCTH) Forecast

Analysts have given Delcath Systems (DCTH) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Delcath Systems (DCTH) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Delcath Systems (DCTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.